TSHR: TSH Receptor Mutations Among a Consanguineous Community

Sponsor
HaEmek Medical Center, Israel (Other)
Overall Status
Completed
CT.gov ID
NCT00747760
Collaborator
National Institutes of Health (NIH) (NIH)
209
2
12
104.5
8.7

Study Details

Study Description

Brief Summary

Resistance to thyrotropin (RTSH) is a condition of impaired responsiveness of the thyroid gland to TSH, characterized by elevated TSH, low or normal thyroid hormone levels, and hypoplastic or normal-sized thyroid gland.

The aim of the present study was to evaluate the clinical course over time,the genotype-phenotype association and the frequency of two different TSH-receptor (TSHR) mutations in a highly consanguineous population of the town of Um-El-Fahem.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Resistance to thyrotropin (RTSH) is a syndrome involving reduced sensitivity to TSH. It is characterized by elevated TSH, absence of goiter (normal or hypoplastic thyroid gland) and normal to very low levels of thyroid hormones. The TSH-receptor (TSHR) gene is located on chromosome 14q31 and it consists of extracellular, trans-membrane and intracellular domains. Mutation in the TSHR may cause either gain or loss of function of the receptor. Loss-of-function mutations are autosomal-recessively inherited and lead to a spectrum of phenotypes, ranging from mild euthyroid hyperthyrotropinemia to severe congenital hypothyroidism (CH). Insensitivity to TSH depends on both the severity and location of the TSHR mutations. Since the first report of familial euthyroid hyperthyrotropinemia caused by a TSHR mutation, several cases of loss-of-function mutations of the TSHR have been reported however only a few reports on the outcome of patients affected with TSHR mutations. Whether the condition of euthyroid hyperthyrotropinemia leads to clinical hypothyroidism, remains stable or normalizes over time has yet to be elucidated. We recently described a unique novel TSHR-inactivating mutation located at the third extracellular loop that preferentially affected the inositol phosphate (IP) pathway in three sisters of Arab-Muslim decent that presented with euthyroid hyperthyrotropinemia. Further analysis of the extended family revealed additional members with TSHR syndrome phenotype carrying two different TSHR mutations. All the affected subjects live in the same town. The aim of the present study was to evaluate the clinical course over time, the genotype-phenotype association and the frequency of these two different TSHR mutations among the highly consanguineous population of the town of Um El Fahem.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    209 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Prevalence of TSH Receptor Mutation Among the Arab Population of Israel
    Study Start Date :
    Dec 1, 2005
    Actual Primary Completion Date :
    Jul 1, 2006
    Actual Study Completion Date :
    Dec 1, 2006

    Arms and Interventions

    Arm Intervention/Treatment
    1

    Extended family members

    2

    Control- subjects from the same town without known thyroid diseases

    Outcome Measures

    Primary Outcome Measures

    1. Two specific TSHR mutations [Finished]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Subjects belonging to extended family of the index case
    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Samuell Refetoff Chicago Illinois United States 60637-1470
    2 Ha'Emek Medical Center Afula Israel 18101

    Sponsors and Collaborators

    • HaEmek Medical Center, Israel
    • National Institutes of Health (NIH)

    Investigators

    • Principal Investigator: Yardena Tenenbaum-Rakover, MD, Ha'Emelk Medical Center,Afula, Israel
    • Principal Investigator: Samuel Refetoff, MD, The University of Chicago, Chicago, Il, USA

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00747760
    Other Study ID Numbers:
    • 920050194
    • 066-2005
    First Posted:
    Sep 5, 2008
    Last Update Posted:
    Sep 11, 2008
    Last Verified:
    Sep 1, 2008
    Keywords provided by , ,
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 11, 2008